Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes.
Frohlich J, Miller MT, Bird LM, Garces P, Purtell H, Hoener MC, Philpot BD, Sidorov MS, Tan WH, Hernandez MC, Rotenberg A, Jeste SS, Krishnan M, Khwaja O, Hipp JF. Frohlich J, et al. Among authors: miller mt. Biol Psychiatry. 2019 May 1;85(9):752-759. doi: 10.1016/j.biopsych.2019.01.008. Epub 2019 Jan 19. Biol Psychiatry. 2019. PMID: 30826071 Free PMC article.
Measuring What Matters to Individuals with Angelman Syndrome and Their Families: Development of a Patient-Centered Disease Concept Model.
Willgoss T, Cassater D, Connor S, Krishnan ML, Miller MT, Dias-Barbosa C, Phillips D, McCormack J, Bird LM, Burdine RD, Claridge S, Bichell TJ. Willgoss T, et al. Among authors: miller mt. Child Psychiatry Hum Dev. 2021 Aug;52(4):654-668. doi: 10.1007/s10578-020-01051-z. Child Psychiatry Hum Dev. 2021. PMID: 32880036 Free PMC article.
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities.
Krishnan ML, Berry-Kravis E, Capal JK, Carpenter R, Gringras P, Hipp JF, Miller MT, Mingorance A, Philpot BD, Pletcher MT, Rotenberg A, Tjeertes J, Wang PP, Willgoss T, de Wit MC, Jeste SS. Krishnan ML, et al. Among authors: miller mt. Nat Rev Drug Discov. 2021 Sep;20(9):653-654. doi: 10.1038/d41573-021-00085-9. Nat Rev Drug Discov. 2021. PMID: 34002058 No abstract available.
Enabling endpoint development for interventional clinical trials in individuals with Angelman syndrome: a prospective, longitudinal, observational clinical study (FREESIAS).
Tjeertes J, Bacino CA, Bichell TJ, Bird LM, Bustamante M, Crean R, Jeste S, Komorowski RW, Krishnan ML, Miller MT, Nobbs D, Ochoa-Lubinoff C, Parkerson KA, Rotenberg A, Sadhwani A, Shen MD, Squassante L, Tan WH, Vincenzi B, Wheeler AC, Hipp JF, Berry-Kravis E. Tjeertes J, et al. Among authors: miller mt. J Neurodev Disord. 2023 Jul 26;15(1):22. doi: 10.1186/s11689-023-09494-w. J Neurodev Disord. 2023. PMID: 37495977 Free PMC article.
AntimiR targeting of microRNA-134 reduces seizures in a mouse model of Angelman syndrome.
Campbell A, Morris G, Sanfeliu A, Augusto J, Langa E, Kesavan JC, Nguyen NT, Conroy RM, Worm J, Kielpinski L, Jensen MA, Miller MT, Kremer T, Reschke CR, Henshall DC. Campbell A, et al. Among authors: miller mt. Mol Ther Nucleic Acids. 2022 Apr 20;28:514-529. doi: 10.1016/j.omtn.2022.04.009. eCollection 2022 Jun 14. Mol Ther Nucleic Acids. 2022. PMID: 35592499 Free PMC article.
151 results